Roundtable nccRCC

Advertisement
Daniel Joyce, MDnccRCC | October 19, 2024
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
View More
Daniel Joyce, MDnccRCC | October 19, 2024
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
Daniel Joyce, MDnccRCC | October 15, 2024
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
Daniel Joyce, MDnccRCC | October 15, 2024
In part 2, new trials in the nccRCC treatment landscape are reviewed, and the use of IO/TKI and PD-L1 are discussed.
Daniel Joyce, MDnccRCC | October 15, 2024
In the first segment of this roundtable series, the panelists discuss the management of papillary metastatic nccRCC.
Laurence Albiges, MD, PhDnccRCC | July 29, 2024
The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC.
Laurence Albiges, MD, PhDnccRCC | July 29, 2024
The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens.
Laurence Albiges, MD, PhDnccRCC | July 29, 2024
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
Laurence Albiges, MD, PhDnccRCC | July 26, 2024
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
Laurence Albiges, MD, PhDnccRCC | July 23, 2024
The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades.
Laurence Albiges, MD, PhDnccRCC | July 23, 2024
The panel explores our understanding of nccRCC, including classification, molecular distinctions, and prognostic criteria.
Advertisement
Advertisement